Allen, J.J., Rack, P.H. & Vaddadi, K.S. (1977). Differences in the effects of clomipramine on English and Asian volunteers: Preliminary report on a pilot study. Postgraduate Medicine, 53(Suppl. 4), 79-86.
2.
Amadi, E., Offiah, N.V. & Akah, P.A. (1991). Neuropyschopharmacologic properties of a Schumanniophyton problematicum root extract. Journal of Ethnopharmacology, 33, 73-77.
3.
Anderson, C.M., Reiss, D.J. & Hogarty, G.E. (Eds). (1986). Schizophrenia and the family: A practitioner's guide to psychoeducation and management. New York: The Guilford Press.
4.
Anderson, K.E., Conney, A.H. & Kappas, A. (1982). Nutritional influences on chemical biotransformations in humans. Nutrition Reviews, 40, 161-169.
5.
Angenent, W.J. & Koelle, G.B. (1953). A possible enzymatic basis for the differential action of mydriatics on light and dark irises. Journal of Physiology, 119, 102-117.
Awad, A.G. (1993). Subjective response to neuroleptics in schizophrenia . Schizophrenia Bulletin, 19, 609-618.
8.
Baldessarini, R. (1985). Chemotherapy in psychiatry: Principles and practice . Cambridge, MA: Harvard Universtiy Press.
9.
Baumann, P. & Eap, C.B. (1988). Alpha1-acid glycoprotein genetics, biochemistry, physiological funtions, and pharmacologyNew York: Alan R. Liss.
10.
Becker, M. & Maiman, L.A. (1980). Strategies for enhancing patient compliance. Journal of Community Health, 6, 113-135.
11.
Becker, M.H. (1985). Patient adherence to prescribed therapies. Medical Care, 23, 539-555.
12.
Bertilsson, L., Alm, C., De Las Carreras, C., Widen, J., Edman, G. & Schalling, D. (1989). Debrisoquine hydroxylation polymorphism and personality . Lancet, 1, 555.
13.
Branch, R.A., Salih, S.Y. & Homeida, M. (1978). Racial differences in drug metabolizing ability: A study with antipyrine in the Sudan. Clinical Pharmacology & Therapeutics, 24, 283-286.
14.
Buckalew, L.W. & Coffield, K.E. (1982). Drug expectations associated with perceptual characteristics: ethnic factors. Perceptual and Motor Skills, 55, 915-918.
15.
Buckalew, L.W. & Ross, S. (1981). Relationship of perceptual characteristics to efficacy of placebos. Psychological Reports, 49, 955-961.
16.
Bunker, C.H., Mallinger, A.G., Adams, L.L. & Kuller, L.H. (1987). Red blood cell sodium-lithium countertransport and cardiovascular risk factors in Black and White college students. Journal of Hypertension, 5, 7-15.
17.
Carbajal, D., Casaco, A., Arruzazabala. L., Gonzalez, R. & Fuentes, V. (1991). Pharmacological screening of plant decoctions commonly used in Cuban folk medicine. Journal of Ethnopharmacology , 33, 21-24.
18.
Chan, C.W. & Chang, J.K. (1976). The role of Chinese medicine in NewYork City's Chinatown. American Journal of Chinese Medicine, 4, 31-45 and 129-146.
19.
Chang, S.S., Pandey, G.N., Zhang, M.Y., Ku, N.F. & Davis, J.M. (1984, May). Racial differences in plasma and RBC lithium levels. Continuing Medical Education Syllabus and Scientific Proceedings (pp. 239-240). 137th Annual Meeting of the American Psychiatric Association, San Francisco: American Psychiatric Association .
20.
Chang, S.S., Pandey, G.N., Yang, Y.Y., Yeh, E.K. & Davis, J.M. (1985, May). Lithium pharmacokinetics: Inter-racial comparison . Paper presented at the 138th Annual Meeting of the American Psychiatric Association. Dallas, Texas .
Chen, A. (1991). Noncompliance in community psychiatry: A review of clinical interventions. Hospital and Community Psychiatry , 42, 282-287.
23.
Cholerton, S., Daly, A.K. & Idle, J.R. (1992). The role of individual human cytochromes P-450 in drug metabolism and clinical response. TiPS Reviews, 13, 434-439.
24.
Clark, W.G., Brater, D.G. & Johnson, A.R. (Eds.). (1988). Goth's Medical Pharmacology. 12th ed. St. Louis: The C.V Mosby Company.
25.
Collard, J. (1962). Drug responses in different ethnic groups. Journal ofNeuropsychiatry, 3(Suppl. 1), 114-121.
26.
Comas-Diaz, L. & Griffith, E.E.H. (Eds.). (1988). Clinical guidelines in cross-cultural mental health. New York: Wiley Series in General and Clinical Psychiatry.
27.
Coryell, W. & Noyes, R. (1988). Placebo response in panic disorder. American Journal of Psychiatry,145, 1138.
28.
Crabtree, B.L., Jann, M.W. & Pitts, W.M. (1991). Alpha1 acid glycoprotein levels in patients with schizophrenia: Effect of treatment with haloperidol. Biological Psychiatry, 29, 43A-185A.
29.
Darmansjah, I. & Muchtar, A. (1992). Dose-response variation among different populations . Clinical Pharmacology & Therapeutics, 47, 626-629.
30.
Denber, H.C.B. & Bente, D. (1967). Clinical response to pharmacotherapy in different settings. In H. Brill et al. (Eds.), Neuropsychopharmacology (pp. 517-520). New York: Excerpta Medica Foundation.
31.
Denber, H.C.B., Bente, D. & Rajotte, P. (1962). Comparative analysis of the action of butyrylperazine at Manhattan State Hospital and the University of Psychiatric Clinic at Erlangen . American Journal of Psychiatry,119, 203-206.
32.
Dimascio, M.A., Havens, L.L. & Klerman, G.L. (1963a). The psychopharmacology of phenothiazine compounds: A comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males. I: Introduction, aims and methods. Journal of Nervous and Mental Disease, 136, 15-28.
33.
Dimascio, M.A., Havens, L.L. & Klerman, G.L. (1963b). The psychopharmacology of phenothiazine compounds: A comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males. II: Results and discussion. Journal of Nervous and Mental Diseases, 136, 168-186.
34.
D'Mello, D.A., McNeil, J.A. & Harris, W. (1989, May). Multiethnic variance in psychiatric diagnosis and neuroleptic dosage. Paper presented at the American Psychiatric Association 142th Annual Meeting, San Francisco, CA.
35.
Dimsdale, J., Ziegler, M. & Graham, R. (1988). The effect of hypertension, sodium, and race on isoproterenol sensitivity. Clinical & Experimental Hypertension: Theory and Practice, A10, 747-756.
36.
Dollery, C.T., Fraser, H.S., Mucklow, J.C. & Bulpitt, C.J. (1979). Contribution of environmental factors to variability in human drug metabolism. Drug Metabolism Reviews, 9, 207-220.
37.
Egashira, T., Sudo, S., Murayama, F., Kono, T., Kudo, Y., Goto, S., Takayama, F. & Yamanaka, Y. (1991). Effects of kamikihi-to, a Chinese traditional medicine, on various cholinergic biochemical markers in the brain of aged rats. Folia Pharmacologica Japonica, 98, 273-281.
38.
Ellis, L. & Nyborg, H. (1992). Racial/ethnic variations in male testosterone levels: A probable contributor to group differences in health. Steroids, 57, 72-75.
39.
Escobar, J.I. & Tuason, V.B. (1980). Antidepressant agents: A cross cultural study . Psychopharmacological Bulletin, 16, 49-52.
40.
Falloon, I.R.H., Boyd, J.L. & McGill, C.W. (Eds). ( 1984). Family care of schizophrenia: A problem-solving approach to the treatment of mental illness. New York: The Guilford Press.
41.
Falloon, I.R.H. & Liberman, R.P. (1983). Interactions between drug and psychosocial therapy in schizophrenia. Schizophrenia Bulletin , 9, 543-554.
42.
Fleishaker, J.C., Smith, T.C., Friedman, H.L. & Hulst, L.K. (1992). Separation of the pharmacokinetic/pharmacodynamic properties of oral and IV adinazolam mesylate and N-desmethyladinazolam mesylate in healthy volunteers. Drug Investigations, 4, 155-165.
43.
Fraser, H.S., Mucklow, J.C., Bulpitt, C.J., Kahn, C., Mould, G. & Dollery, C.T. (1979). Environmental factors affecting antipyrine metabolism in London factory and office workers. British Journal of Clinical Pharmacology, 7, 237-243.
44.
Garde, J.F., Aston, R., Endler, G.C. & Sison, O.S. (1978). Racial mydriatic response to belladonna premedication . Anesthesia and Analgesia, 57, 572-576.
45.
Gaviria, M., Gil, A.A. & Javaid, J.I. (1986). Nortriptyline kinetics in Hispanic and Anglo subjects . Journal of Clinical Psychopharmacology, 6, 227-231.
46.
Ghoneim, M.M., Korttila, K., Chiang, C.K., Jacobs, L., Schoenwald, R.D., Newaldt, S.P. & Lauaba, K.O. (1981). Diazepam effects and kinetics in Caucasians and Orientals. Clinical Pharmacology and Therapeutics, 29, 749-756.
47.
Gillis, L.S., Trollip, D., Jakoet, A. & Holden, T. (1987). Non-compliance with psychotropic medication. South African Medical Journal, 72, 602-606.
48.
Goldberg, S.C., Schooler, N.R., Davidson, E.M. & Kayce, M.M. (1966). Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia ( Berlin) 9, 31-47.
49.
Gonzalez, F.J. (1989). The molecular biology of cytochrome P-450s. Pharmacological Reviews, 40, 243-288.
50.
Gonzalez, F.J. & Nebert, D.W. (1990). Evolution of the P-450 gene superfamily: animal-plant "warfare", molecular drive and human genetic differences in drug oxidation . Trends in Genetics, 6, 182-186.
51.
Gonzalez, F.J. (1992). Human cytochromes P-450: Problems and prospects . TiPS Reviews, 13, 346-352.
52.
Greenblatt, D.J. (1993). Basic pharmacokinetic principles and their application to psychotropic drugs. Journal of Clinical Psychiatry, 54 (Suppl.) 8-13.
53.
Harding, T.W. & Chrusciel, T.L. (1975). The use of psychotropic drugs in developing countries. Bulletin of the World Health Organization, 52, 359-367.
54.
Heilizer, F. (1960). A critical review of some published experiments with chlorpromazine in schizophrenic, neurotic, and normal humans. Journal of Chronic Diseases, 11, 102-148.
55.
Hogarty, G.E., McEVOY, J.P., Munetz, M., Dibarry, A.L., BARTONE, P. Cather, R., Cooley, S.J., ULRICH, R.E, Carter, M. & Madonia, M.J. (1988). Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry,45, 797-805.
56.
Hu, W.H., Lee, C.F., Yang, Y.Y. & Tseng, Y.T. (1983). Imipramine plasma levels and clinical response. Bulletin of Chinese Society of Neurology andPsychiatry, 9, 40-49.
57.
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten,A., COOPER, J.E., DAY, R. & BERTELSEN, A. (1992). Schizophrenia: manifestations, incidence and course in different cultures: A World Health Organization ten-country study. Psychological Medicine, 20, 1-97.
58.
Jacobs, K.W. & Nordan, F.M. (1979). Classification of placebo drugs: Effect of color . Perceptual and Motor Skills, 49, 367-372.
59.
Janke, W. (1983). Response variability to psychotropic drugs: Overview of the main approaches to differential pharmacopsychology. In W. Janke (Ed.), Response variability to psychotropic drugs (pp. 217-260). New York: Pergamon Press.
60.
Jann, M.W., Chang, W.H., Davis, C.M., Chen, T.Y., Deng, H.C., Lung, F.W., Ereshefsky, L., Saklad, S.R. & Richards, A.L. (1989). Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients . Psychiatry Research, 30, 45-52.
61.
JANN, M.W., LAM, Y.W. & CHANG, W.H. (1993). Haloperidol and reduced haloperidol plasma concentrations in different ethnic populations and interindividual variabilities in haloperidol metabolism. In K.M. Lin, R.E. Poland & G. Nakasaki (Eds.), Psychopharmacology and psychobiology of ethnicity (pp. 133-152). Washington, DC: American Psychiatric Press.
62.
Jenkins, J.H. & Karno, M. (1992). The meaning of expressed emotion: Theoretical issues raised by cross-cultural research. American Journal of Psychiatry,149, 9-21.
63.
Juneja, R.K., Weitkamp, L.R., Stratil, A., Gahne, B. & Guttormsen, S.A. ( 1988). Further studies of the plasma α1 B-glycoprotein polymorphism: Two new alleles and allele frequencies in Caucasians and in American Blacks. Human Heredity, 38, 267-272.
64.
Kalow, W. (1989). Race and therapeutic drug response. New England Journal of Medicine, 320, 588-589.
65.
Kalow, W. (1990). Pharmacogenetics: Past and future. Life Sciences, 47, 1385-1397.
66.
Kalow, W. (1991). Interethnic variation of drug metabolism. Trends in Pharmacological Sciences, 12, 102-107.
67.
Kalow, W. (Ed.). (1992). Pharmacogenetics of Drug Metabolism. New York: Pergamon Press.
68.
Kalow, W. (1993). Pharmacogenetics: Its biologic roots and the medical challenge. Clinical Pharmacology and Therapeutics. 54, 235-241. Kawazu, Y., Nakano , S. & Ogawa, N. (1980). Personality trait and antianxiety drug effects on psychomotor performance . Neuro-Psychopharmacology , 4, 285-292.
69.
Keefe, S.E., Padilla, A.M. & Carlos, M.L. (1978). Emotional support systems in two cultures: A comparison of Mexican-Americans and Anglo Americans. (Available from University of California at Los Angeles, Spanish Speaking Mental Health Center .)
70.
Kinzie, J.D., Leung, P., Boehnlein, J. & Fleck, J. (1987). Tricyclic antidepressant plasma levels in Indochinese refugees: Clinical implication. Journal of Nervous Mental Disorders, 175, 480-485.
71.
Kirmayer, L.J. & Robbins, J.M. (Eds.). (1991). Current concepts of somatization, research and clinical perspectives. Washington, DC: American Psychiatric Press.
72.
Kishimoto, A. & Hollister, L.E. (1984). Nortriptyline kinetics in Japanese and Americans [Letter to the editor]. Journal of Clinical Psychopharmacology, 4, 171-172.
73.
Kleinman, A. (1980). Patients and healers in the context of culture . Berkeley, University of California Press.
74.
Kleinman, A. (1988). Rethinking psychiatry. New York: The Free Press. Kremer, J.M.H., Wilting, J. & Janssen, L.H.M. (1988). Drug binding to human alpha-1-acid glycoprotein in health and disease . Pharmacological Reviews, 40, 1-45.
75.
Kumana, C.R., Lauder, I.J., CHAN, M., KO, W. & LIN, H.J. (1987). Differences in diazepam pharmacokinetics in Chinese and White Caucasians: Relation to body lipid stores. European Journal of Clinical Pharmacology, 32, 211-215.
76.
Lee, S. ( 1993). Side effects of chronic lithium therapy in Hong Kong Chinese: An ethnopsychiatric perspective. Culture, Medicine and Psychiatry, 17, 301-320.
77.
Levy, R.H. & Moreland, T.A. (1984). Rationale for monitoring free drug levels. Clinical Pharmacokinetics, 9 (Suppl. 1), 1-9.
78.
Lewis, W.H., Kennelly, E.J., Bass, G.N., Wedner, H.J., Elvin-Lewis, M.P. & Fast, D. (1991). Ritualistic use of the holly ilex guayusa by Amazonian Jivaro Indians. Journal of Ethnopharmacology, 33, 25-30.
79.
Ley, P. & Spelman, M.S. (1967). Communicating with the patient. London: Staples Press.
80.
Lidwig, E.G. & Collete, J. (1970). Dependency, social isolation and mental health in a disabled population. Social Psychiatry, 5, 92- 95.
81.
Lieberman, J.A., Yunis, J., Egea, E., Canoso, R.T., Kane, J.M. & Yunis, E.J. (1990). HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry,47, 945-948.
82.
Lieberman, P.B. & Strauss, J.S. (1984). The recurrence of mania: Environmental factors and medical treatment. American Journal of Psychiatry,141, 77-80.
83.
Lin, K.M. (1987). Experiences on inpatient wards: Taiwan vs Los Angeles. American Journal of Social Psychiatry, 7, 220-225.
84.
Lin, K.M. & Kleinman, A.M. (1988). Psychopathology and clinical course of schizophrenia: A cross-cultural perspective. Schizophrenia Bulletin, 14, 555-567.
85.
Lin, K.M., Lau, J.K., Smith, R. & Poland, R.E. (1988b). Comparison of alprazolam plasma levels and behavioral effects in normal Asian and Caucasian male volunteers. Psychopharmacology , 96, 365-369.
86.
Lin, K.M., Miller, M.M., Nuccio, I. & Yamaguchi, M. (1991). Ethnicity and family involvement in the treatment of schizophrenic patients. Journal of Nervous Mental Disorders , 179, 626-628.
87.
Lin, K.M., Poland, R.E., Lau, J.& Rubin, R.T. (1988a). Haloperidol and prolactin concentrations in Asians and Caucasians. Journal of Clinical Psychopharmacology, 8, 195-201.
88.
Lin, K.M., Poland, R.E. & Lesser, I. (1986). Ethnicity and psychopharmacology. Culture, Medicine & Psychiatry, 10, 151-165.
89.
Lin, K.M., Poland, R.E. & Nakasaki, G. (Eds.) ( 1993). Psychopharmacology and psychobiology of ethnicity. Washington, DC: American Psychiatric Press.
90.
Lin, K.M., Poland, R.E., Nuccio, I., Matsuda, K., Hathuc, N., Su, T.P. & Fu, P. (1989). Longitudinal assessment of haloperidol dosage and serum concentration in Asian and Caucasian schizophrenic patients. American Journal of Psychiatry, 146, 1307-1311.
91.
Lin, K.M. & Shen, W.W. (1991). Pharmacotherapy for Southeast Asian psychiatric patients. Journal of Nervous and Mental Disease, 179, 346-350.
92.
Liu, G.T. (1991). Effects of some compounds isolated from Chinese medicinal herbs on hepatic microsomal cytochrome P-450 and their potential biological consequences. Drug Metabolism Reviews, 23, 439-465.
93.
Livingston, R.L., Zucker, D.K., Isenberg, K. & Wetzel, R.D. (1983). Tricyclic antidepressants and delirium. Journal of Clinical Psychiatry, 44, 173-176.
94.
Loebel, A.D., Hyde, T.S. & Dunner, D.L. (1986). Early placebo response in anxious and depressed patients. Journal of Clinical Psychiatry, 47, 230-233.
95.
Lundh, L.G. (1987). Placebo, belief, and health: A cognitive-emotional model. Scandinavian Journal of Psychology, 28, 128-143.
96.
Mail, P.D., McKAY, R.B. & Katz, M. (1989). Expanding practice horizons: Learning from American Indian patients. Patient Education and Counseling, 13, 91-102.
97.
Marcolin, M.A., Stiers, W. & Chung, Y.S. (1991, May). Racial differences in schizophrenia when controlling for economic status. Continuing Medical Education Syllabus and Scientific Proceedings, (pp. 80-81). American Psychiatric Association, 144th Annual Meeting, New Orleans, Louisiana .
98.
Marcus, L.R. & Cancro, R. (1982). Pharmacotherapy of Hispanic depressed patients: Clinical observations. American Journal of Psychotherapy, 36, 505-512.
99.
Masuda, M. & Bakker, C.B. (1966). Personality, catecholamine metabolites, and psychophysiological response to cliazepam. Journal of Psychiatric Research, 4,, 221-234.
100.
Mavissakalian, M. (1987a). The placebo effect in agoraphobia. Journal of Nervous and Mental Disease, 175, 95-99.
101.
Mavissakalian, M. (1987b). The placebo effect in agoraphobia-II. Journal of Nervous and Mental Disease, 176, 446-448.
102.
Mavissakalian, M.R., Jones, B. & Olson, S. (1990). Absence of placebo response in obsessive-compulsive disorder. Journal of Nervous and Mental Disease, 178, 268-270.
103.
McGoldrick, M., Pearce, J.K. & Giordano, J. (Eds.). (1982). Ethnicity and family therapy. New York: The Guilford Press.
104.
Midha, K.K., Hawes, E.M., Hubbard, J.W., Korchinski, E.D. & McKay, G. (1988a). A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology, 95, 333-338.
105.
Midha, K.K., Hawes, E.M., Hubbard, J.W., Korchinski, E.D. & McKay G. (1988b). Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology , 96, 206-211.
106.
Mishler, E.G. & Scotch, N.A. (1963). Sociocultural factors in the epidemiology of schizophrenia: A review. Psychiatry, 26, 315-351.
107.
Mofrman, D.E. (1979). Anthropology of symbolic healing. Currents in Anthropology, 20, 59-80.
108.
Moser, M. & Lunn, J. (1981). Comparative effects of pindolol and hydrochlorothiazide in Black hypertensive patients. Angiology, 32, 561-566.
109.
Murphy, H.B.M. (1969). Ethnic variations in drug responses. Transcultural Psychiatric Research Review, 6, 6-23.
Murray, M. & Reidy, G.F. (1990). Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacology Review, 42, 2-101.
112.
Myers, J.K., Lindenthal J.J., Pepper, M.P. & Ostrander, D.R. (1972). Life events and mental status: A longitudinal study. Journal of Health & Social Behavior, 13, 398-406.
113.
Nakano, S., Ogawa, N. & Kawazu, Y. (1980). Influence of neuroticism on oral absorption of diazepam. Clinical Pharmacology and Therapeutics, 27, 370-374.
114.
Nall, F.C. & Speilberg, J. (1978). Social and cultural factors in the responses of Mexican Americans to medical treatment. In R.A. Martinez (Ed.), Hispanic culture and health care: Fact, fiction, and folklore (pp. 51-64). St. Louis: C.V Mosby.
115.
Nelson, E., Stason, W., Neutra, R. & Solomon, H.S. (1980). Identification of noncompliant hypertensive patients . Preventive Medicine, 9, 504-517.
116.
Nuñez, F. (1976). Variations in fulfillment of expectations of social interaction and morale among aging Mexican-Americans and Anglos. Unpublished master's thesis, University of Southern California.
117.
Okey, A.B. (1992). Enzyme induction in the cytochrome P-450 system . In W. Kalow (Ed.) Pharmacogenetics of drug metabolism (pp. 549-608). New York: Pergamon Press.
118.
Okpaku, S., Frazer, A. & Mendels, J. (1980). A pilot study of racial differences in erythrocyte lithium transport. American Journal of Psychiatry,137, 120-121.
119.
Olatawura, M.O. (1978). The effects of psychotropic drugs in different populations. Bulletin of the World Health Organization, 56, 519-523.
120.
Ostrow, D.G., Dorus, W., Okonek, A., Desai, P., Bauer, J., Bresolin, L.B. & Davis, J.M. (1986). The effect of alcoholism on membrane lithium transport . Journal of Clinical Psychiatry, 47, 350-353.
121.
Parrott, A.C. & Kentridge, R. (1982). Personal constructs of anxiety under the 1,5-benzodiazepine derivative clobazam related to trait-anxiety levels of the personality. Psychopharmacology, 78, 353-357.
122.
Pfister, G.M., Hanson, D.R., Roerig, J.L., Landbloom, R. & Popkin, M.K. (1992). Clozapine-induced agranulocytosis in a Native American: HLA typing and further support for an immune-mediated mechanism . Journal of Clinical Psychiatry, 53, 242-244.
123.
Pi, E.H., Simpson, G.H. & Cooper, M.A. (1986). Pharmacokinetics of desipramine in Caucasian and Asian volunteers. American Journal of Psychiatry, 143, 1174-1176.
124.
Pi, E.H., Tran-Johnson, T.K., Walker, N.R., Cooper, R.B., Suckow, R.F. & Gray, G.E. (1989). Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacology Bulletin, 25, 483-487.
125.
Potkin, S.G., Shen, Y., Pardes, H., Phelps, B.H., ZHOU, D., SHU, L., KORPI, E. & WYATT, R.J. (1984). Haloperidol concentrations elevated in Chinese patients. Psychiatry Research, 12, 167-172.
126.
Preskorn, S.H. (1993). Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. Journal of Clinical Psychiatry , 54(Suppl.), 14-34.
127.
Price, N.D., Glazer, W.M. & Morgenstern, H. (1985). Race and the use of fluphenazine decanoate. American Journal of Psychiatry,142, 1491-1492.
128.
Priebe, S. (1987). Early subjective reactions predicting the outcome of hospital treatment in depressive patients. Acta Psychiatrica Scandinavica, 76, 134-138.
129.
Rabkin, J.G., McGrath, P.J., Quitkin, F.M., Tricamo, E., Stewart, J.W. & Klein, D.F. (1990). Effects of pill-giving on maintenance of placebo response in patients with chronic mild depression. American Journal of Psychiatry,147, 1622-1626.
130.
Reidenberg, M.M. & Erill, S. (Eds.). (1986). Drug-protein binding. NewYork: Oxford University Press.
131.
Rosenblat, R. & Tang, S.W. (1987). Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with Occidentals?Canadian Journal of Psychiatry, 32, 270-274.
132.
Routledge, P.A. (1986). The plasma protein binding of basic drugs. British Journal of Clinical Pharmacology, 22, 499-506.
133.
Rudorfer, M.V. (1993). Pharmacokinetics of psychotropic drugs in special populations. Journal of Clinical Psychiatry, 54(Suppl.), 50-54.
134.
Rudorfer, M.V., Lane, E.A., Chang, W.H., Zhang, M.D. & Potter, W.Z. (1984). Desipramine pharmacokinetics in Chinese and Caucasian volunteers. British Journal of Clinical Pharmacology17, 433-440.
135.
Rudorfer, M.V. & Robins, E. (1982). Amitriptyline overdose: Clinical effects on tricyclic antidepressant plasma levels. Journal of Clinical Psychiatry , 43, 457-460.
136.
Rutledge, D.R., Steinberg, M.B. & Cardozo, L. (1989). Racial differences in drug response: Isoproterenol effects on heart rate following intravenous metoprolol. Clinical Pharmacology & Therapeutics, 45, 380-386.
137.
Sackett, D.L. & Haynes, R.B. (Eds.). (1976). Compliance with therapeutic regimens. Baltimore & London : The Johns Hopkins Press.
138.
Sankury, T. (1983). Lead poisoning from Mexican folk remedies—Califor— nia (letter). JAMA, 250, 3149.
139.
Sartorius, N. (1980). The research component of the WHO mental health program. Psychological Medicine, 10, 175-185.
140.
Schneider, L., Pawluczyk, S., Dopheide, J., Lyness, S.A., Suckow, R.F. & Copper, T.B. (1991, May). Ethnic differences in nortriptyline metabolism. New Research Program and Abstracts (pp. 206). American Psychiatric Association, 144th Annual Meeting, New Orleans, Louisiana.
141.
Shader, R.I. & Greenblatt, D.J. (1988). Bees, ginseng and MAOI's revisited. Journal of Clinical Psychopharmacology, 8, 325.
142.
Shawcross, C.R. & Tyrer, P. (1985). Influence of personality on response to monoamine oxidase inhibitors and tricyclic antidepressants. Journal of Psychiatric Research, 19, 557-562.
143.
Shen, W.W. & Lin, K.M. (1990). Cytochrome P-450 monooxygenases and interactions of psychotropic drugs. International Journal of Psychiatry in Medicine, 21, 21-30.
144.
SILVER, B., LIN, K.M. & POLAND, R.E. (1993). Ethnicity and the pharmacology of tricyclic antidepressants. In K.M. Lin, R.E. Poland & G. Nakasaki (Eds.), Psychopharmacology and psychobiology of ethnicity (pp. 61-89). Washington DC: American Psychiatric Press.
145.
Slater, P.E. & Kastenbaum, R. (1966). Paradoxical reactions to drugs: Some personality and ethnic correlates. Journal of the American Geriatrics Society14, 1016-1034.
146.
SMITH, M., LIN, K.M. & MENDOZA, R. (1993). "Non-biological" issues affecting psychopharmacotherapy: Cultural considerations. In K.M. Lin, R.E. Poland & G. Nakasaki (Eds.), Psychopharmacology and psychobiology of ethnicity (pp. 37-58). Washington, DC: American Psychiatric Press.
147.
Someya, T., Sibasaki, M., Noguchi, T., Takahashi, S. & Inaba, T. (1992). Haloperidol metabolism in psychiatric patients: Importance of glucuronidation and carbonyl reduction. Journal of Clinical Psychopharmacology, 12, 169-174.
148.
Spiker, D.G. & Kupfer, D.J. (1988). Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders, 14, 21-23.
149.
Strickland, T., Lin, K.M., Fu, P., Anderson, D. & Zheng, Y.P. (in press). RBC lithium ratio variation among African American and Caucasian bipolar patients. Biological Psychiatry.
150.
Takahashi, R. (1979). Lithium treatment in affective disorders: Therapeutic plasma level. Psychopharmacology Bulletin, 15, 32-35.
151.
Tseng, W.S. & McDermott, J.F. , JR. (1981). Culture, mind & therapy: An introduction to cultural psychiatry. New York : Brunner/Mazel.
152.
Van Putten, T. & May, P.R. (1978). Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Archives of General Psychiatry, 35, 477-480.
153.
Vermeer, D.E. & Farrell, R.E. (1985). Nigerian geophagical clay: A traditional antidiarrheal pharmaceutical. Science, 227, 634-636.
154.
Weber, W.W. (1987). The acetylator genes and drug responses. New York: Oxford University Press.
155.
Westermeyer, J. (1989a). Psychiatric care of migrants: A clinical guide . Washington, DC: American Psychiatric Press.
156.
Westermeyer, J. (1989b). Mental health for refugees and other migrants . Springfield, IL: Charles C. Thomas Publishing.
157.
White, L., Tursky, B. & Schwartz, G.E. (Eds.). (1985 ). Placebo: Theory, research and mechanisms. New York: The Guilford Press.
Wood, A.J. & Zhou, H.H. (1991). Ethnic differences in drug disposition and responsiveness . Clinical Pharmacokinetics, 20, 1-24.
160.
World Health Organization (1979). Schizophrenia: An international follow-up study. Chichester : John Wiley & Sons.
161.
World Health Organization (1986). Dose effects of antidepressant medication in different populations. Journal of Affective Disorders, (Suppl. 2), 1-67.
162.
WORLD HEALTH ORGANIZATION (1990). Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet, 336, 955.
163.
Yamahara, J., Kobayashi, M., Matsuda, H. & Aoki, S. (1991). Anticholinergic action of Swertia Japonica and an active constituent. Journal of Ethnopharmacology, 33, 31-35.
164.
Yamashita, I. & Asano, Y. (1979). Tricyclic antidepressants: Therapeutic plasma level. Psychopharmacology Bulletin, 15, 40-41.
165.
Yang, YY (1985). Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatrica Scandinavica, 71, 171-175.
166.
Yoshida, A. (1993). Genetic polymorphisms of alcohol-metabolizing enzymes related to alcohol sensitivity and alcoholic diseases. In K.M. Lin, R.E. Poland & G. Nakasaki (Eds.), Psychopharmacology and Psychobiology of Ethnicity (pp.169-186). Washington, DC: American Psychiatric Press.
167.
Zhang, Y., Reviriego, J., Lou, Y., Sjoqvist, F. & Bertilsson, L. (1990). Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects. Clinical Pharmacology & Therapeutics, 48, 496-502.
168.
Zhou, H.H., Adedoyin, A. & Wilkinson, G.R. (1990). Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clinical Pharmacology and Therapeutics, 48, 10-17.
169.
Zhou, H.H., Koshakji, R.P., Siolberstein, D.J., Wilkinson, G.R. & Wood, A.J.J. (1989). Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. New England Journal of Medicine, 320, 565-570.
170.
Ziegler, VE & Biggs, J.T. (1977). Tricyclic plasma levels: Effect of age, race, sex, and smoking. Journal of the American Medical Association , 438, 2167-2169.
171.
Zito, J.M., Craig, T.J., Wanderling, J. & Seigel, C. (1987). Pharmacoepidemiology in 136 hospitalized schizophrenic patients. American Journal of Psychiatry144, 778-782.
